Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- EGFRi rash severity
研究概览
简要总结
This research is being done to study whether using of topical tretinoin can help prevent the common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I) medications such ascetuximab or erlotinib.
Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and topical or oral antibiotics. However, there has not yet been a study looking at a way to prevent this common side effect from occurring, and topical tretinoin may be useful in reducing the rash.
Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing rashes associated with EGFR-I's.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or over
- •Scheduled to begin treatment with an EGFR inhibitor drug
排除标准
- •Pregnant or nursing
- •History of bleeding disorder
- •History of keloids or large, thick, puffy-looking scars in the last 10 years
- •Used topical retinoids in the last year (e.g. tretinoin/Retin-A, adapalene/Differin, tazarotene/Tazorac)
研究组 & 干预措施
Tretinoin pre-treatment
干预措施: Tretinoin (Drug)
结局指标
主要结局
EGFRi rash severity
时间窗: 8 weeks
次要结局
未报告次要终点
研究者
Anna Chien
Assistant Professor, Co-Director, Cutaneous Translational Research Program
Johns Hopkins University